Abstract
Glial cells are integrated part of neurovascular unit of blood brain barrier (BBB). They undergo mitosis and mainly classified as astrocytes, oligodendrocytes, microglia, ependymal cells and nerve glial antigen 2 cells. Being a most versatile glial cell, astrocytes provide structural support to neurons, maintain brain homeostasis, take part in neuronal communication, and perform some housekeeping functions. Oligodendrocytes myelinate the neuronal axons for proper transmission of nerve impulse and microglia are brain immune cells. Multiple sclerosis is a prototype glia mediated disease that manifests demyelination. Fingolimod is already being marketed for this disease, while guanabenz and ibudilast are facing clinical trials. Many researches revealed the role of glial cells in Alzheimer’s disease, in which riluzole (a glutamate modulator already in market for amyotrophic lateral sclerosis-ALS) was found to be effective. Q-cells® are glial cell-based therapeutic agent to treat ALS that only produce astrocytes and oligodendrocytes, when transplanted in vivo. hIL13-PE is a gene based therapeutic agent that has been smartly designed for the treatment of glioma. Although for CNS diseases, drugs are available, still it is not easy to extract satisfactory therapeutic effect of most of the drugs due to the presence of BBB. This barrier can be overcome by implanting a drug reservoir in brain parenchyma (wafer), by judicious selection of drug delivery system (nanoparticulate system), or by using an alternative route of administration (intranasal route). This review revolves around cellular and drug based modulation of glial cells to achieve maximum therapeutic benefit for some of the CNS diseases.
Keywords: Central nervous system, glial cells, blood-brain barrier, multiple sclerosis, cancer, pharmacotherapy, gene therapy, nanotechnology.
Current Pharmaceutical Design
Title:Glial Cell: A Potential Target for Cellular and Drug Based Therapy in Various CNS Diseases
Volume: 23 Issue: 16
Author(s): Shakeeb Ahmed, Azka Gull, Tahir Khuroo, Mohd. Aqil and Yasmin Sultana*
Affiliation:
- Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, New Delhi,India
Keywords: Central nervous system, glial cells, blood-brain barrier, multiple sclerosis, cancer, pharmacotherapy, gene therapy, nanotechnology.
Abstract: Glial cells are integrated part of neurovascular unit of blood brain barrier (BBB). They undergo mitosis and mainly classified as astrocytes, oligodendrocytes, microglia, ependymal cells and nerve glial antigen 2 cells. Being a most versatile glial cell, astrocytes provide structural support to neurons, maintain brain homeostasis, take part in neuronal communication, and perform some housekeeping functions. Oligodendrocytes myelinate the neuronal axons for proper transmission of nerve impulse and microglia are brain immune cells. Multiple sclerosis is a prototype glia mediated disease that manifests demyelination. Fingolimod is already being marketed for this disease, while guanabenz and ibudilast are facing clinical trials. Many researches revealed the role of glial cells in Alzheimer’s disease, in which riluzole (a glutamate modulator already in market for amyotrophic lateral sclerosis-ALS) was found to be effective. Q-cells® are glial cell-based therapeutic agent to treat ALS that only produce astrocytes and oligodendrocytes, when transplanted in vivo. hIL13-PE is a gene based therapeutic agent that has been smartly designed for the treatment of glioma. Although for CNS diseases, drugs are available, still it is not easy to extract satisfactory therapeutic effect of most of the drugs due to the presence of BBB. This barrier can be overcome by implanting a drug reservoir in brain parenchyma (wafer), by judicious selection of drug delivery system (nanoparticulate system), or by using an alternative route of administration (intranasal route). This review revolves around cellular and drug based modulation of glial cells to achieve maximum therapeutic benefit for some of the CNS diseases.
Export Options
About this article
Cite this article as:
Ahmed Shakeeb, Gull Azka, Khuroo Tahir , Aqil Mohd. and Sultana Yasmin *, Glial Cell: A Potential Target for Cellular and Drug Based Therapy in Various CNS Diseases, Current Pharmaceutical Design 2017; 23 (16) . https://dx.doi.org/10.2174/1381612823666170316124500
DOI https://dx.doi.org/10.2174/1381612823666170316124500 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NUPR1 Interacts with p53, Transcriptionally Regulates p21 and Rescues Breast Epithelial Cells from Doxorubicin-Induced Genotoxic Stress
Current Cancer Drug Targets Chemosensitization of Prostate Carcinoma Cells with a Receptor-directed Smac Conjugate
Medicinal Chemistry Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Biocompatible Targeting Hydrogels for Breast Cancer Treatment
Mini-Reviews in Medicinal Chemistry Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy The Role of Carrier Geometry in Overcoming Biological Barriers to Drug Delivery
Current Pharmaceutical Design Mechanism of Drug Sensitivity and Resistance in Melanoma
Current Cancer Drug Targets Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents
Current Medicinal Chemistry Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Polysialyltransferase: A New Target in Metastatic Cancer
Current Cancer Drug Targets Identification of Small Molecule Sulfonic Acids as Ecto-5'-Nucleotidase Inhibitors
Medicinal Chemistry New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology A Potencial Theranostic Agent for EGF-R Expression Tumors: 177Lu- DOTA-Nimotuzumab
Current Radiopharmaceuticals